Jennifer C Keenan, Arielle J Medford, Charles S Dai, Seth A Wander, Laura M Spring, Aditya Bardia
{"title":"针对激素受体阳性乳腺癌的新型口服选择性雌激素受体降解剂（SERDs）：以艾乐司群为代表。","authors":"Jennifer C Keenan, Arielle J Medford, Charles S Dai, Seth A Wander, Laura M Spring, Aditya Bardia","doi":"10.1080/14737140.2024.2346188","DOIUrl":null,"url":null,"abstract":"Estrogen receptor positive (ER+) breast cancer is the most common breast cancer subtype, and therapeutic management relies primarily on inhibiting ER signaling. In the metastatic setting, ER signal...","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"100 1","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: Elacestrant as the poster-child.\",\"authors\":\"Jennifer C Keenan, Arielle J Medford, Charles S Dai, Seth A Wander, Laura M Spring, Aditya Bardia\",\"doi\":\"10.1080/14737140.2024.2346188\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Estrogen receptor positive (ER+) breast cancer is the most common breast cancer subtype, and therapeutic management relies primarily on inhibiting ER signaling. In the metastatic setting, ER signal...\",\"PeriodicalId\":12099,\"journal\":{\"name\":\"Expert Review of Anticancer Therapy\",\"volume\":\"100 1\",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-04-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anticancer Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737140.2024.2346188\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2346188","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: Elacestrant as the poster-child.
Estrogen receptor positive (ER+) breast cancer is the most common breast cancer subtype, and therapeutic management relies primarily on inhibiting ER signaling. In the metastatic setting, ER signal...
期刊介绍：
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
